hotspot -WSS

hotspot

author：hotspot 2025-09-27 10:52:11 - browse：25757

0:53FILE PHOTO: Elon Musk, Chief Executive Officer of SpaceX and Tesla and owner of Twitter, gestures as he attends the Viva Technology conference dedicated to innovation and startups at the Porte de Versailles exhibition centre in Paris, France, June 16, 2023. REUTERS/Gonzalo Fuentes/File PhotoGonzalo Fuentes/Reuters

Elon Musk said Saturday that Twitter is struggling with a "heavy debt load" due to losing 50% of advertising revenue, resulting in the platform having a negative cash flow.

"We’re still negative cash flow, due to ~50% drop in advertising revenue plus heavy debt load. Need to reach positive cash flow before we have the luxury of anything else," Musk tweeted to a user.

Musk took over Twitter last October in a deal costing roughly $44 billion. Almost immediately, Musk began making changes to the company, cutting about 75% of its workforce, leaving many with concerns about Twitter's ability to maintain its platform.

FILE PHOTO: Elon Musk, Chief Executive Officer of SpaceX and Tesla and owner of Twitter, gestures as he attends the Viva Technology conference dedicated to innovation and startups in Paris, France, June 16, 2023. REUTERS/Gonzalo Fuentes/File Photo — FILE PHOTO: Elon Musk, Chief Executive Officer of SpaceX and Tesla and owner of Twitter, gestures as he attends the Viva Technology conference dedicated to innovation and startups at the Porte de Versailles exhibition centre in Paris, France, June 16, 2023. REUTERS/Gonzalo Fuentes/File PhotoGonzalo Fuentes/Reuters

In an interview with BBC in April, Musk said Twitter was "roughly" breaking even, going on to say most of the advertisers had returned.

MORE: A timeline of Elon Musk's tumultuous Twitter acquisition

In May, Musk announced that ex-NBCUniversal advertising executive Linda Yaccarino would be Twitter's new CEO.

Yaccarino's hiring seemingly implied a refreshed focus on advertising after Musk tried to develop the company's revenue through a rebranded version of its subscription service after phasing out legacy "blue check marks."

MORE: Twitter sends Meta cease-and-desist letter over new Threads app: Sources

Forbes India has Musk valued as the richest man in the world, with an alleged net worth of $245.9 billion, with two-thirds of that worth being tied to Tesla's success.

Just this month, Twitter found itself competing with Mark Zuckerberg's company, Meta, after it launched Threads, a 'conversation app' that has been dubbed the "Twitter killer" and had over 100 million users sign up in just the first two weeks.

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： A new drug could help frostbite victims avoid its ravages

hotspot

WSS

A new approach to psychiatric drug development

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Measles policy set amid Florida outbreak alarms vaccine proponents

Measles policy set amid Florida outbreak alarms vaccine proponents

Medicare Advantage enrollment hits roughly 33.4 million

leisure time

hotspot

MORE: A timeline of Elon Musk's tumultuous Twitter acquisition

MORE: Twitter sends Meta cease-and-desist letter over new Threads app: Sources

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Surprise medical billing ban raises prices elsewhere

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Affirmative action in medical school literally saved lives

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Walensky prepares to leave CDC — and Congress — behind

A new drug could help frostbite victims avoid its ravages

Medicare proposal to cover medical devices draws a mixed reaction

Medicare Advantage enrollment grows 7.1% to 33.4 million people

explore

Medicare Advantage enrollment hits roughly 33.4 million

Medicare Advantage enrollment grows 7.1% to 33.4 million people

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Researchers tackle phage therapy hurdles for wider adoption

Families look for replacement for GSK asthma drug Flovent

MD Anderson's Padmanee Sharma responds to research credit suit

hotspot

hotspot

hotspot

hotspot